UK Approves Eli Lilly's Once-Daily Weight-Loss Pill

Britain's medicines regulator has authorised Eli Lilly's oral GLP-1 medicine orforglipron, marketed as Foundayo, for weight management and type 2 diabetes, opening another front in the rapidly expanding market for obesity treatments.

The approval makes the UK the first European country to authorise Lilly's tablet. Unlike established injectable medicines such as Mounjaro, the new treatment is taken orally once each day. The medicine works through the GLP-1 pathway, which plays an important role in regulating appetite, blood sugar and feelings of fullness.

Lilly's drug has already been approved in the United States, where regulators authorised it in April following late-stage trials that showed substantial weight reduction among patients taking the medicine.

The UK approval intensifies competition between Lilly and Danish pharmaceutical group Novo Nordisk. Britain's regulator approved an oral version of Novo's weight-loss treatment in June, making the country one of the earliest markets in the escalating competition over weight-management tablets.

Oral medicines could prove commercially important because some patients may prefer tablets to weekly injections. They may also be easier to manufacture and distribute at scale, potentially helping pharmaceutical companies meet enormous international demand for obesity treatment.

However, regulatory approval does not mean the medicine will immediately be routinely available through the NHS. Reuters reported that Foundayo is not currently available on the NHS, meaning questions around cost effectiveness, pricing, eligibility and public funding remain to be resolved.

This distinction is significant because demand for GLP-1 medicines has grown rapidly while NHS access remains tightly controlled.

Medicines used for weight management are not cosmetic treatments. They are generally intended for people meeting defined clinical criteria and are prescribed alongside dietary, physical-activity and wider health measures.

The arrival of another oral option could eventually increase patient choice, but it also reinforces concerns over online prescribing, counterfeit products and unsafe use of weight-loss medicines outside proper medical supervision.

The next major question is therefore not whether Britain has authorised the medicine, but how quickly patients will actually be able to obtain it - and at what cost.

Source attribution: Medicines and Healthcare products Regulatory Agency information reported by Reuters; Eli Lilly; Reuters.